KDCA Begins Efficacy Evaluation of Delta and Omicron Variants for 'SK바사' Vaccine
Post-Omicron Response
[Asia Economy Reporter Jo In-kyung] The Korea Disease Control and Prevention Agency's National Institute of Health announced on the 28th that it has begun the 'variant virus neutralization evaluation' for the domestically developed COVID-19 vaccine by SK Bioscience.
The neutralization evaluation measures the amount of neutralizing antibodies that can inhibit coronavirus infection.
The National Institute of Health completed the analysis of priority samples used in the phase 3 clinical trial of the SK Bioscience vaccine last March.
However, since the vaccine was developed based on the 'Wuhan strain' that spread in the early stages of the COVID-19 pandemic, there was an opinion that efficacy verification against the Delta and Omicron variants, which have recently spread or are currently spreading in Korea, is also necessary, leading to this evaluation.
Hot Picks Today
At President Lee's Call to "Give Enough to Shock," Whistleblower Rewards Become a Real Lottery
- If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Kwon Jun-wook, director of the National Institute of Health, said, "As COVID-19 variants continue to emerge, we must strengthen our proactive response capabilities to new variant outbreaks," adding, "We will support variant virus evaluations for domestically developed vaccines using various platforms, including mRNA (messenger ribonucleic acid) vaccines, centered on the Public Vaccine Development Support Center of the National Infectious Disease Research Institute."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
